Cargando...
Heterogeneity in refractory acute myeloid leukemia
Successful clinical remission to therapy for acute myeloid leukemia (AML) is required for long-term survival to be achieved. Despite trends in improved survival due to better supportive care, up to 40% of patients will have refractory disease, which has a poorly understood biology and carries a dism...
Gardado en:
| Publicado en: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
National Academy of Sciences
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535032/ https://ncbi.nlm.nih.gov/pubmed/31064876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1902375116 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|